0001225208-12-016969.txt : 20120801
0001225208-12-016969.hdr.sgml : 20120801
20120801135731
ACCESSION NUMBER: 0001225208-12-016969
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120730
FILED AS OF DATE: 20120801
DATE AS OF CHANGE: 20120801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HUMAN GENOME SCIENCES INC
CENTRAL INDEX KEY: 0000901219
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 223178468
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 14200 SHADY GROVE ROAD
CITY: ROCKVILLE
STATE: MD
ZIP: 20850-3338
BUSINESS PHONE: 3013098504
MAIL ADDRESS:
STREET 1: 14200 SHADY GROVE ROAD
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MORROW GEORGE J
CENTRAL INDEX KEY: 0001068754
STANDARD INDUSTRIAL CLASSIFICATION: STATE COMMERCIAL BANKS [6022]
STATE OF INCORPORATION: NC
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14169
FILM NUMBER: 12999455
MAIL ADDRESS:
STREET 1: AMGEN INC.
STREET 2: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320-1799
4
1
doc4.xml
X0306
4
2012-07-30
1
0000901219
HUMAN GENOME SCIENCES INC
HGSI
0001068754
MORROW GEORGE J
14200 SHADY GROVE ROAD
ROCKVILLE
MD
20850
1
Common Stock
2012-07-30
4
D
0
4166.0000
14.2500
D
10834.0000
D
Common Stock
2012-07-30
4
U
0
10834.0000
14.2500
D
0.0000
D
Non-Employee Director Stock Option - Right to Buy
14.2300
2012-07-30
4
D
0
16000.0000
14.2500
D
2022-05-17
Common Stock
16000.0000
0.0000
D
Each restricted stock unit represents a contingent right to receive one (1) share of Human Genome Sciences, Inc. common stock. These restricted stock units were cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $59,365.50, ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These restricted stock units vested automatically upon consummation of the tender offer on July 30, 2012.
This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $320.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
/s/James H. Davis (Power of Attorney) on behalf of
2012-08-01